Daniel Flicker joined Novo Ventures (US) Inc. in 2022 as an Associate in the Boston office. Daniel was previously an Associate in healthcare investment banking at Chardan, where he originated and executed capital raises for pre-commercial life sciences companies. He also spent time on Chardan’s equity research team, where his coverage focused on disruptive platforms in genetic medicines. Prior to Chardan, Daniel worked at L.E.K. Consulting in the Life Sciences & Pharma practice.
Daniel holds a Ph.D. in Systems Biology from Harvard University and a B.A. in Biochemistry from Columbia University.